Stockscreener 앱 받기
228.63
0.72%
-1.65
시간 외 거래:
228.63
전일 마감가:
$230.28
열려 있는:
$231.28
하루 거래량:
738.76K
Relative Volume:
0.78
시가총액:
$16.09B
수익:
$2.71B
순이익/손실:
$247.10M
주가수익비율:
65.31
EPS:
3.5008
순현금흐름:
$349.90M
1주 성능:
-3.15%
1개월 성능:
-8.22%
6개월 성능:
-30.89%
1년 성능:
-13.99%
1일 변동 폭
$226.26
$232.18
1주일 범위
$216.49
$233.26
52주 변동 폭
$216.49
$354.88
인슐렛 코퍼레이션 Stock (PODD) Company Profile
명칭
Insulet Corporation
전화
978-600-7000
주소
100 NAGOG PARK, ACTON, MA
Compare PODD vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PODD
Insulet Corporation
|
228.63 | 16.21B | 2.71B | 247.10M | 349.90M | 3.5008 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
인슐렛 코퍼레이션 Stock (PODD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-27 | 재개 | TD Cowen | Hold |
| 2026-01-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-12-16 | 개시 | Evercore ISI | Outperform |
| 2025-11-19 | 업그레이드 | UBS | Neutral → Buy |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 재개 | Oppenheimer | Outperform |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-05-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-04-29 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-03-06 | 개시 | RBC Capital Mkts | Outperform |
| 2024-11-06 | 개시 | Bernstein | Outperform |
| 2024-05-30 | 개시 | Redburn Atlantic | Buy |
| 2024-05-07 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2023-12-21 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-12-04 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-02 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-21 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-08-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-01-26 | 개시 | Wolfe Research | Peer Perform |
| 2022-11-04 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-02-02 | 업그레이드 | UBS | Neutral → Buy |
| 2022-01-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-19 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2021-01-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-07-28 | 개시 | Wells Fargo | Overweight |
| 2020-04-24 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-04-03 | 개시 | BofA/Merrill | Neutral |
| 2020-03-31 | 다운그레이드 | Berenberg | Buy → Hold |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-10 | 개시 | CFRA | Sell |
| 2019-10-23 | 개시 | Stifel | Hold |
| 2019-10-18 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2019-10-14 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2019-10-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-10-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-06 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-06-10 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-05-06 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-04-20 | 개시 | Berenberg | Buy |
| 2018-02-22 | 재확인 | Barclays | Overweight |
| 2018-01-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2017-11-03 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2017-09-15 | 개시 | Barclays | Overweight |
모두보기
인슐렛 코퍼레이션 주식(PODD)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - PR Newswire
Insulet Corporation $PODD Shares Sold by JPMorgan Chase & Co. - MarketBeat
Alecta Tjanstepension Omsesidigt Increases Stake in Insulet Corporation $PODD - MarketBeat
PODD Investor Alert: Insulet Corp. Potential Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Executives Allegedly Misled on Safety: Levi & Korsinsky - PR Newswire
Securities Fraud Investigation Into Insulet Corporation (PODD) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentInsulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Insulet Gains 62.9% in a Year: What's Driving the Stock? - MSN
Insulet Corp. Stock Hits Day Low of $216.51 Amid Price Pressure - Markets Mojo
Insulet Corp. Hits New 52-Week Low at $216.51 Amid Market Challenges - Markets Mojo
Volatility Watch: Can Insulet Corporation deliver alpha2026 Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet ... - Bluefield Daily Telegraph
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insulet CorporationPODD - FinancialContent
Insulet Corp. stock outperforms competitors on strong trading day - MarketWatch
ATTENTION Insulet Corporation (PODD) Investors: Possible FraudContact Levi & Korsinsky Today - The Globe and Mail
Insulet recalling certain defective Omnipod insulin delivery devices - MSN
Momentum Shift: Does Insulet Corporation stock benefit from AI growth2026 Big Picture & Community Verified Trade Alerts - baoquankhu1.vn
Insulet Corp. stock underperforms Friday when compared to competitors - MSN
Insulet Surges 2.19% as Earnings and Buys Outweigh Recall Risks Traded at 448th Volume Rank - Bitget
Insulet recalls specific Omnipod 5 insulin pump lots after injuries - Investing.com Nigeria
Insulet stock (ISIN: US45784P1012): Insulin Pump Maker Faces Competitive Pressure Amid Rising Health - AD HOC NEWS
Insulet to spend up to $40M on insulin pump recall - Worcester Business Journal
Jain Global LLC Purchases 63,719 Shares of Insulet Corporation $PODD - MarketBeat
Insulet Stock Drops 7% After Omnipod 5 Recall - TIKR.com
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment - The Motley Fool
Cinctive Capital Management LP Makes New $6.69 Million Investment in Insulet Corporation $PODD - MarketBeat
Diabetic insulin pods recalled for manufacturing issue - NewsNation
How The Insulet (PODD) Narrative Is Shifting With Omnipod 5 And Rising Competition - Yahoo Finance
What Insulet (PODD)'s Omnipod 5 Pod Correction and Trial Data Reveal for Shareholders - Sahm
Is It Time To Reassess Insulet (PODD) After Recent Share Price Weakness - Yahoo Finance
Insulet Stock To $154? - Trefis
Why Insulet (PODD) Is Down 7.2% After Omnipod 5 Recall Over Insulin Under-Delivery Risk - Yahoo Finance
Insulet Corporation stock hits 52-week low at 226.14 USD By Investing.com - Investing.com India
Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Securities Fraud Investigation Into Insulet Corporation (PODD) An - The National Law Review
Insulet recalls specific Omnipod 5 insulin pump lots after injuries By Investing.com - Investing.com Australia
Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - lincolnjournal.com
Insulet Corporation (PODD) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - WFXG
Insulet recalls some insulin devices in US over leakage risk - Reuters
FDA announces recall of insulin delivery pods - Cardiovascular Business
Securities Fraud Investigation Into Insulet Corporation (PODD) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - The AI Journal
Insulet to spend up to $40M on Omnipod 5 pod recall - The Business Journals
Insulet Down Nearly 7%, on Track for Lowest Close Since September 2024 -- Data Talk - 富途牛牛
Insulet initiates Omnipod 5 recall following 18 AE reports - Yahoo Finance
Insulet Corporation stock hits 52-week low at 226.14 USD - Investing.com Nigeria
Insulet falls as Omnipod 5 Pod medical device correction spotlights manufacturing issue - Quiver Quantitative
Insulin devices recalled over leak risk, reports of 'serious adverse events' - LiveNOW from FOX
Insulet reports 18 serious adverse events with recall of Omnipod 5 insulin pumps - MedTech Dive
Insulet (NASDAQ:PODD) Sets New 12-Month LowShould You Sell? - MarketBeat
Insulet (PODD) Faces Stock Dip After Voluntary Device Correction - GuruFocus
Insulet Begins Voluntary Medical Device Correction for Certain Omnipod 5 Pods in the U.S. - Medical Product Outsourcing
Insulet Stock Hits 52-Week Low - Benzinga
인슐렛 코퍼레이션 (PODD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):